The IDIBELL research group on immunoinflammatory processes demonstrates that the C4BP (β-) protein could be a promising therapeutic option for inflammatory bowel disease.
The work has analyzed the interaction of the IKKα protein with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing the toxicity of the treatment.
The group has applied these classification recommendations to 128 variants reported in the literature and/or public databases, classifying 17 as pathogenic variants, and another 17 as benign.
Genetic studies that initially gave uncertain results can provide a reliable diagnosis if reviewed after two years
This Saturday took place the open day of the fifth edition of Sinergia, the celebration of health research and innovation in L’Hospitalet. More than 300 people came to the Bellvitge Campus to take part in the everyday work of that IDIBELL, the Catalan Institute of Oncology, the Bellvitge University Hospital, the University of Barcelona and the Hospital Sant Joan de Déu do to improve people’s health.
Absolute success of the Sinergia 2023 open day Read More »
A new study carried out by the Nutrition and Cancer research group of IDIBELL and the Catalan Institute of Oncology, with the collaboration of the scientific and technological center AZTI, offers a relevant review and update of data that demonstrates how eating habits and the microbiota intestine could play a key role in cancer prevention.
The new treatment is a drug that eliminates the antibodies that bind to gram-negative bacteria and makes them resistant to destruction by the immune system.
On the morning of Saturday, October 21, the 5th edition of Sinergia will bring the science of the Bellvitge Campus closer to citizens.
Sinergia will open its doors to Bellvitge health research and innovation Read More »
When the RANK protein was suppressed in luminal cells of the breast tissue in female mice, they did not produce milk in their first pregnancy.
ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.
The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round Read More »
